Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure formula (I) enantiomers, diastereomers, solvates, salts, tautomers or prodrugs thereof wherein, A, W, X, Y and R1 are defined herein.
Type:
Grant
Filed:
July 2, 2007
Date of Patent:
November 27, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jeffrey A. Robl, Shung C. Wu, David S. Yoon
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, A, B, D, E, G, Y, Z, R1 and R2 are defined herein.
Abstract: Compounds of formula Ia and Ib and wherein A, B, C and R1 are described herein.
Type:
Grant
Filed:
June 10, 2010
Date of Patent:
November 6, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Jianqing Li, John Lloyd, Michael M. Miller, Zulan Pi, Jennifer X. Qiao, Richard A. Rampulla, Jacques Y. Roberge, Tammy C. Wang, Yufeng Wang, Wu Yang
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-Beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: enantiomers, diastereomers, solvates, or salts thereof, wherein A, W, X and Z are defined herein.
Type:
Grant
Filed:
April 14, 2010
Date of Patent:
October 30, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Xiang-Yang Ye, Jeffrey A. Robl, Ronald L. Hanson, Zhiwei Guo, Ramesh N. Patel
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are defined herein.
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.
Type:
Grant
Filed:
June 14, 2011
Date of Patent:
July 31, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dean A. Wacker, Karen A. Rossi, Ying Wang
Abstract: A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.
Type:
Grant
Filed:
March 7, 2011
Date of Patent:
May 15, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dean A. Wacker, Karen A. Rossi, Ying Wang
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: W-L-Z??(I) or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein W, L and Z are defined herein.
Type:
Grant
Filed:
July 27, 2009
Date of Patent:
April 17, 2012
Inventors:
James J. Li, Lawrence G. Hamann, Haixia Wang
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof wherein W, L, R3, R3a, R3b and R4 are defined herein.
Type:
Grant
Filed:
April 16, 2009
Date of Patent:
April 3, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
James J. Li, Lawrence G. Hamann, Haixia Wang, Zheming Ruan, Christopher B. Cooper, Jun Li, Jeffrey A. Robl
Abstract: Novel heterocyclic aromatic compounds are provided that are useful in stimulating endogenous production or release of growth hormone, said compounds having the general structure of formula I wherein R1, R1a, R6, Xa, Xb and Y are as described herein. The compounds provided herein are useful in treating obesity, osteoporosis (improving bone density) and in improving muscle mass and muscle strength.
Type:
Grant
Filed:
October 11, 2005
Date of Patent:
March 27, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
William R. Ewing, Jun Li, Richard B. Sulsky, Andres S. Hernandez
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein G, Q, X, Y, R3, R3a, and R3b are defined herein.
Type:
Grant
Filed:
September 9, 2008
Date of Patent:
February 21, 2012
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jun Li, Jeffrey A. Robl, James J. Li, Lawrence J. Kennedy, Haixia Wang, Jie Jack Li, Xinhua Qian, Rajendra P. Deshpande, Laxma R. Kolla, Reginald O. Cann, Chenkou Wei, Michael Galella
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n2, n3, n4, A, B, D, E, G, J, Y, R1 and R2 are defined herein.
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, A, B, D, E, G, Y, Z, R1 and R2 are defined herein.
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure Formula I or Formula IA.
Type:
Grant
Filed:
July 16, 2008
Date of Patent:
August 23, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dean A. Wacker, Karen A. Rossi, Ying Wang
Abstract: A method of modulating the activity of the GPR119 G protein-coupled receptor comprising administering to a mammalian patient in need thereof a therapeutically effective amount of at least one compound of Formula I or Formula IA and, optionally, an additional therapeutic agent.
Type:
Grant
Filed:
July 16, 2008
Date of Patent:
April 19, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Dean A. Wacker, Karen A. Rossi, Ying Wang
Abstract: Novel compounds are provided which are GPR119 G protein-coupled receptor modulators. GPR119 G protein-coupled receptor modulators are useful in treating, preventing, or slowing the progression of diseases requiring GPR119 G protein-coupled receptor modulator therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein n1, n2, n3, n4, A, B, D, E, G, Y, Z, R1 and R2 are defined herein.
Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
Type:
Grant
Filed:
November 15, 2006
Date of Patent:
February 15, 2011
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark E. Salvati, Heather Finlay, Lalgudi S. Harikrishnan, Ji Jiang, James A. Johnson, Muthoni G. Kamau, R. Michael Lawrence, Michael M. Miller, Jennifer X. Qiao, Tammy C. Wang, Yufeng Wang, Wu Yang
Abstract: Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds have the structure: or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein.
Type:
Grant
Filed:
February 28, 2007
Date of Patent:
November 16, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Jun Li, Jeffrey A. Robl, Lawrence J. Kennedy
Abstract: The present application describes modulators of MCP-1 of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma.
Type:
Grant
Filed:
January 15, 2009
Date of Patent:
November 9, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Percy H. Carter, Robert J. Cherney, Douglas G. Batt, John V. Duncia, Daniel S. Gardner, Soo S. Ko, Anurag S. Srivastava, Michael G. Yang
Abstract: The present invention provides modulators of serotonin receptors, pharmaceutical compositions containing such modulators and methods for treating various diseases, conditions and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compounds and compositions.
Type:
Grant
Filed:
May 14, 2007
Date of Patent:
October 12, 2010
Assignee:
Bristol-Myers Squibb Company
Inventors:
Guohua Zhao, Chet Kwon, Philip D. Stein